Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Welcome and Introduction to Vi3C

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Jun

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Welcome and Introduction to Vi3C

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Overall Survival With EBRT in Hepatocellular Carcinoma

HCC TACE Plus STRIDE With or Without Lenvatinib

St Jude Redesignation Marks Collaboration With WHO Toward Improved Pediatric Cancer Outcomes Globally

FDA Warns of Ongoing Breast Biopsy Needle Shortage

New ACSM Expert Consensus Statement: Exercise in Children and Adolescents With Cancer